IN2014MN02000A - - Google Patents

Download PDF

Info

Publication number
IN2014MN02000A
IN2014MN02000A IN2000MUN2014A IN2014MN02000A IN 2014MN02000 A IN2014MN02000 A IN 2014MN02000A IN 2000MUN2014 A IN2000MUN2014 A IN 2000MUN2014A IN 2014MN02000 A IN2014MN02000 A IN 2014MN02000A
Authority
IN
India
Prior art keywords
solid crystalline
ynamide
pyrirnidin
dihydroquinazolin
arnino
Prior art date
Application number
Other languages
English (en)
Inventor
Rudy Laurent Maria Broeckx
Walter Ferdinand Maria Filliers
Patrick Hubert J Nieste
Alex Herman Copmans
Filip Marcel C Vanhoutte
Carina Leys
Original Assignee
Respivert Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49160309&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2014MN02000(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Respivert Ltd filed Critical Respivert Ltd
Publication of IN2014MN02000A publication Critical patent/IN2014MN02000A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IN2000MUN2014 2012-03-13 2013-03-13 IN2014MN02000A (OSRAM)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261610023P 2012-03-13 2012-03-13
US201261610012P 2012-03-13 2012-03-13
PCT/GB2013/050624 WO2013136076A1 (en) 2012-03-13 2013-03-13 Crystalline pi3 kinase inhibitors

Publications (1)

Publication Number Publication Date
IN2014MN02000A true IN2014MN02000A (OSRAM) 2015-08-14

Family

ID=49160309

Family Applications (2)

Application Number Title Priority Date Filing Date
IN1998MUN2014 IN2014MN01998A (OSRAM) 2012-03-13 2013-03-13
IN2000MUN2014 IN2014MN02000A (OSRAM) 2012-03-13 2013-03-13

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IN1998MUN2014 IN2014MN01998A (OSRAM) 2012-03-13 2013-03-13

Country Status (35)

Country Link
US (3) US9642799B2 (OSRAM)
EP (2) EP2825202B1 (OSRAM)
JP (3) JP6189874B2 (OSRAM)
KR (2) KR20140131971A (OSRAM)
CN (2) CN104302650B (OSRAM)
AU (2) AU2013234081B2 (OSRAM)
CA (2) CA2864652A1 (OSRAM)
CL (2) CL2014002386A1 (OSRAM)
CO (2) CO7061079A2 (OSRAM)
CR (2) CR20140416A (OSRAM)
CY (1) CY1118565T1 (OSRAM)
DK (1) DK2834244T3 (OSRAM)
EA (2) EA025465B1 (OSRAM)
EC (2) ECSP14018142A (OSRAM)
ES (2) ES2650791T3 (OSRAM)
GT (2) GT201400182A (OSRAM)
HR (1) HRP20161383T1 (OSRAM)
HU (1) HUE029420T2 (OSRAM)
IL (2) IL233886A (OSRAM)
IN (2) IN2014MN01998A (OSRAM)
LT (1) LT2834244T (OSRAM)
MX (2) MX355299B (OSRAM)
MY (1) MY171125A (OSRAM)
NI (2) NI201400100A (OSRAM)
NZ (2) NZ627963A (OSRAM)
PE (2) PE20141964A1 (OSRAM)
PH (2) PH12014501713A1 (OSRAM)
PL (1) PL2834244T3 (OSRAM)
PT (1) PT2834244T (OSRAM)
SG (2) SG11201404522VA (OSRAM)
SI (1) SI2834244T1 (OSRAM)
TW (2) TWI617561B (OSRAM)
UA (1) UA115544C2 (OSRAM)
WO (2) WO2013136075A1 (OSRAM)
ZA (2) ZA201407373B (OSRAM)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0918249D0 (en) 2009-10-19 2009-12-02 Respivert Ltd Compounds
UY33337A (es) 2010-10-18 2011-10-31 Respivert Ltd DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
SG11201404522VA (en) 2012-03-13 2014-10-30 Respivert Ltd Crystalline pi3 kinase inhibitors
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
KR20150079745A (ko) 2012-11-08 2015-07-08 리젠 파마슈티컬스 소시에떼 아노님 Pde4 억제제 및 pi3 델타 또는 이중 pi3 델타-감마 키나아제 억제제를 함유하는 약제학적 조성물
AR095353A1 (es) 2013-03-15 2015-10-07 Respivert Ltd Compuesto
JO3279B1 (ar) 2013-03-15 2018-09-16 Respivert Ltd مشتقات 2-((4- امينو -3- (3- فلورو-5- هيدروكسي فينيل)-h1- بيرازولو [d-3,4] بيرمدين-1-يل )ميثيل )- 3- (2- تراي فلورو ميثيل ) بينزيل ) كوينازولين -4 (h3)- واحد واستخدامها كمثبطات فوسفواينوسيتايد 3- كاينيز
SG10201902074UA (en) 2013-10-04 2019-04-29 Infinity Pharmaceuticals Inc Heterocyclic compounds and uses thereof
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN113616656B (zh) 2014-03-19 2023-02-17 无限药品股份有限公司 用于治疗PI3K-γ介导的障碍的杂环化合物
MX2017000208A (es) 2014-07-04 2017-05-01 Lupin Ltd Derivados de quinolizinona como inhibidores de pi3k.
US20180021256A1 (en) * 2014-07-09 2018-01-25 Arven Ilac Sanayi Ve Ticaret A.S. Process for the preparation of formulations for inhalation
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
AU2016322552B2 (en) 2015-09-14 2021-03-25 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
SG11201809042SA (en) * 2016-04-15 2018-11-29 Chia Tai Tianqing Pharmaceutical Group Co Ltd Inhaled preparation of isoglycyrrhizic acid or salt thereof, and use in preparing drugs for treating respiratory system diseases
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1204826B (it) 1986-03-04 1989-03-10 Chiesi Farma Spa Composizioni farmaceutiche per inalazione
GB9501841D0 (en) 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
WO1999028979A2 (en) 1997-12-02 1999-06-10 Alcatel Usa Sourcing, L.P. Digital phone system
HU226164B1 (en) * 1998-11-13 2008-05-28 Jagotec Ag Use of magnesium stearate in dry powder compositions suitable for inhalation and compositions suitable for inhalation
CA2369895C (en) 1999-01-11 2010-12-21 Princeton University High affinity inhibitors for target validation and uses thereof
PT1158958E (pt) 1999-03-05 2007-08-13 Chiesi Farma Spa ''composições farmacêuticas em pó, melhoradas, para inalação''
PE20011227A1 (es) 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
US6608053B2 (en) 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
KR100774855B1 (ko) 2000-04-27 2007-11-08 아스텔라스세이야쿠 가부시키가이샤 축합 헤테로아릴 유도체
EP1217000A1 (en) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
WO2003006628A2 (en) 2001-07-13 2003-01-23 Virtual Drug Development, Inc. Nad synthetase inhibitors and uses thereof
AU2002317377A1 (en) 2001-07-20 2003-03-03 Cancer Research Technology Limited Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer
AU2003301662A1 (en) 2002-10-21 2004-05-13 Bristol-Myers Squibb Company Quinazolinones and derivatives thereof as factor xa inhibitors
JP4736043B2 (ja) 2003-03-14 2011-07-27 小野薬品工業株式会社 含窒素複素環誘導体およびそれらを有効成分とする薬剤
US7122557B2 (en) 2003-03-18 2006-10-17 Bristol-Myers Squibb Company Sulfonyl-amidino-containing and tetrahydropyrimidino-containing compounds as factor Xa inhibitors
EP1625165A2 (en) 2003-04-03 2006-02-15 Protein Design Labs, Inc. Inhibitors of integrin alpha5beta1 and their use for the control of tissue granulation
US7429596B2 (en) 2003-06-20 2008-09-30 The Regents Of The University Of California 1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof
GB0316341D0 (en) * 2003-07-11 2003-08-13 Glaxo Group Ltd Pharmaceutical formulations
JP2009513529A (ja) * 2003-07-11 2009-04-02 グラクソ グループ リミテッド ステアリン酸マグネシウムを含む医薬製剤
US20100267778A1 (en) 2003-08-04 2010-10-21 Shinya Kusuda Diphenyl ether compound, process for producing the same, and use
US20050043239A1 (en) 2003-08-14 2005-02-24 Jason Douangpanya Methods of inhibiting immune responses stimulated by an endogenous factor
WO2005016349A1 (en) 2003-08-14 2005-02-24 Icos Corporation Methods of inhibiting leukocyte accumulation
GB0326632D0 (en) 2003-11-14 2003-12-17 Jagotec Ag Dry powder formulations
US20050239809A1 (en) 2004-01-08 2005-10-27 Watts Stephanie W Methods for treating and preventing hypertension and hypertension-related disorders
ES2873875T3 (es) * 2004-05-13 2021-11-04 Icos Corp Quinazolinonas como inhibidores de fosfatidilinositol 3-quinasa delta humano
CA2730540A1 (en) 2004-05-13 2005-12-01 Vanderbilt University Phosphoinositide 3-kinase delta selective inhibitors for inhibiting angiogenesis
WO2005117889A1 (en) 2004-05-25 2005-12-15 Icos Corporation Methods for treating and/or preventing aberrant proliferation of hematopoietic
EP1750715A1 (en) 2004-06-04 2007-02-14 Icos Corporation Methods for treating mast cell disorders
AU2005283326B2 (en) 2004-09-13 2011-07-21 Ono Pharmaceutical Co., Ltd. Nitrogenous heterocyclic derivative and medicine containing the same as an active ingredient
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
US20080287469A1 (en) 2005-02-17 2008-11-20 Diacovo Thomas G Phosphoinositide 3-Kinase Inhibitors for Inhibiting Leukocyte Accumulation
GB0525254D0 (en) 2005-12-12 2006-01-18 Jagotec Ag Powder compositions for inhalation
SI2004654T1 (sl) 2006-04-04 2013-11-29 The Regents Of The University Of California Pirazolopirimidinski derivati za uporabo kot kinazni antagonisti
KR20090017498A (ko) 2006-04-04 2009-02-18 더 리젠트스 오브 더 유니이버시티 오브 캘리포니아 Ｐｉ３ 키나제 길항물질
CA2652886A1 (en) 2006-05-24 2007-11-29 Bayer Schering Pharma Aktiengesellschaft High affinity human and humanized anti-.alpha.5.beta.1 integrin function blocking antibodies with reduced immunogenicity
MX2009000107A (es) 2006-06-29 2009-01-23 Schering Corp Antagonistas del receptor de trombina biciclicos y triciclicos sustituidos.
GB0622818D0 (en) 2006-11-15 2006-12-27 Jagotec Ag Improvements in or relating to organic compounds
EP2081892A4 (en) 2006-11-17 2014-03-05 Donald F Weaver COMPOUNDS AND METHOD FOR THE TREATMENT OF PROTEIN DISAPPEARANCE
WO2008067219A2 (en) 2006-11-29 2008-06-05 Kalypsys, Inc. Quinazolinone modulators of tgr5
US8338437B2 (en) 2007-02-28 2012-12-25 Methylgene Inc. Amines as small molecule inhibitors
US20100305113A1 (en) * 2007-05-09 2010-12-02 Hans-Georg Capraro Substituted Imidazopyridazines as Lipid Kinase Inhibitors
WO2008140750A1 (en) 2007-05-10 2008-11-20 Hydra Biosciences Inc. Compounds for modulating trpv3 function
WO2009088990A1 (en) 2008-01-04 2009-07-16 Intellikine, Inc. Certain chemical entities, compositions and methods
CA2738429C (en) 2008-09-26 2016-10-25 Intellikine, Inc. Heterocyclic kinase inhibitors
US20110269779A1 (en) 2008-11-18 2011-11-03 Intellikine, Inc. Methods and compositions for treatment of ophthalmic conditions
AU2009322187B2 (en) 2008-12-04 2015-02-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Phosphatidylinositol-3-kinase p110 delta-targeted drugs in the treatment of CNS disorders
US8658648B2 (en) 2008-12-05 2014-02-25 Designmedix, Inc. Modified chloroquines with single ring moiety or fused ring moiety
US20110135655A1 (en) 2009-01-13 2011-06-09 PHILADELPHIA HEALTH AND EDUCATION CORPORATION d/b/a Drexel University College of Medicine; Role of PI3K p110 delta Signaling in Retroviral Infection and Replication
MX2011009955A (es) 2009-03-24 2011-11-18 Gilead Calistoga Llc Atropisomeros de derivados de 2-purinil-3-tolil-quinazolinona y metodos de uso.
BR112012002331A2 (pt) 2009-08-05 2019-09-24 Versitech Ltd composição antiviral, composição farmacêutica e uso de quantidade efetiva de composição farmacêutica
GB0918249D0 (en) 2009-10-19 2009-12-02 Respivert Ltd Compounds
WO2011083387A1 (en) 2010-01-07 2011-07-14 Pfizer Limited Hydrochloride salt of biphenyl-2-yl-carbamic acid 1-{9-[(3-fluoro-4-hydroxy-benzoyl)-methyl-amino]-nonyl}-piperidin-4-yl ester
CN201676365U (zh) 2010-03-29 2010-12-22 山东京卫制药有限公司 带有语音提示的给药吸入装置
CN201692450U (zh) 2010-06-22 2011-01-05 于清 用于药物输送的高效干粉吸入器
WO2012028663A1 (en) * 2010-08-31 2012-03-08 Glaxo Group Limited Dry powder inhalation drug products exhibiting moisture control properties and methods of administering the same
RU2580890C2 (ru) 2010-09-30 2016-04-10 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Применение стеарата магния в составах сухого порошка для ингаляции
UY33337A (es) 2010-10-18 2011-10-31 Respivert Ltd DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
CN202154919U (zh) 2011-05-03 2012-03-07 王晓明 一种防交叉感染雾化吸入装置
SG11201404522VA (en) 2012-03-13 2014-10-30 Respivert Ltd Crystalline pi3 kinase inhibitors

Also Published As

Publication number Publication date
IL233883A0 (en) 2014-09-30
NZ628072A (en) 2015-08-28
ZA201407374B (en) 2016-10-26
CN104284679B (zh) 2017-08-04
EP2825202B1 (en) 2017-09-06
SG11201404522VA (en) 2014-10-30
UA115544C2 (uk) 2017-11-27
NZ627963A (en) 2015-08-28
MX2014010990A (es) 2014-10-13
MX2014010991A (es) 2014-10-13
DK2834244T3 (en) 2016-11-28
IN2014MN01998A (OSRAM) 2015-08-14
SI2834244T1 (sl) 2016-12-30
SG11201404519UA (en) 2014-10-30
AU2013234081B2 (en) 2017-02-02
WO2013136075A1 (en) 2013-09-19
EP2834244A1 (en) 2015-02-11
ZA201407373B (en) 2016-10-26
EA025465B1 (ru) 2016-12-30
AU2013234081A1 (en) 2014-08-21
TW201400484A (zh) 2014-01-01
JP2018008992A (ja) 2018-01-18
HK1203812A1 (en) 2015-11-06
EP2825202A1 (en) 2015-01-21
KR20140131971A (ko) 2014-11-14
ES2600705T3 (es) 2017-02-10
CO7061079A2 (es) 2014-09-19
HUE029420T2 (en) 2017-02-28
CY1118565T1 (el) 2017-07-12
CO7051030A2 (es) 2014-09-10
ECSP14018630A (es) 2015-09-30
AU2013234080A1 (en) 2014-08-21
JP2015509972A (ja) 2015-04-02
GT201400183A (es) 2015-07-08
US20150105408A1 (en) 2015-04-16
AU2013234080B2 (en) 2016-12-22
PH12014501922A1 (en) 2014-11-24
CA2864643A1 (en) 2013-09-19
CL2014002386A1 (es) 2015-02-27
NI201400101A (es) 2016-11-30
LT2834244T (lt) 2016-11-10
HK1203487A1 (zh) 2015-10-30
EA201491674A1 (ru) 2014-12-30
NI201400100A (es) 2015-01-12
TW201350139A (zh) 2013-12-16
MY171125A (en) 2019-09-26
CN104284679A (zh) 2015-01-14
CN104302650A (zh) 2015-01-21
PT2834244T (pt) 2016-11-03
CL2014002385A1 (es) 2015-01-09
PH12014501713A1 (en) 2014-10-13
HRP20161383T1 (hr) 2016-12-02
CA2864652A1 (en) 2013-09-19
EA023715B1 (ru) 2016-07-29
JP2015509973A (ja) 2015-04-02
PE20141964A1 (es) 2014-12-01
IL233886A (en) 2017-12-31
MX355299B (es) 2018-04-11
EA201491675A1 (ru) 2014-12-30
CR20140417A (es) 2014-10-31
JP6189874B2 (ja) 2017-08-30
ES2650791T3 (es) 2018-01-22
TWI617561B (zh) 2018-03-11
PE20142342A1 (es) 2015-01-16
EP2834244B1 (en) 2016-08-10
ECSP14018142A (es) 2015-06-30
TWI586378B (zh) 2017-06-11
CN104302650B (zh) 2017-07-18
GT201400182A (es) 2015-09-17
US9642799B2 (en) 2017-05-09
MX357170B (es) 2018-06-27
US20150099768A1 (en) 2015-04-09
US20170239256A1 (en) 2017-08-24
KR20140141596A (ko) 2014-12-10
PL2834244T3 (pl) 2017-01-31
WO2013136076A1 (en) 2013-09-19
CR20140416A (es) 2014-10-31

Similar Documents

Publication Publication Date Title
IN2014MN02000A (OSRAM)
EP2576578A4 (en) POLYMORPHES OF 2'-O-FUCOSYLLACTOSE AND MANUFACTURE THEREOF
BR112015000229A2 (pt) formulações aquosas estáveis de etanercept
IN2014CN04530A (OSRAM)
PH12016500057A1 (en) Novel indolizine compounds, a process for their preparation and pharmaceutical compositions containing them
IN2014DN01992A (OSRAM)
WO2013004995A8 (en) Pyrimidinone compounds and their use
MX2013013557A (es) Derivados de alcoholes 1-fenil-2-piridinil alquilicos como inhibidores de fosfodiesterasa.
MX353847B (es) Composicion farmaceutica de rosuvastatina calcica.
WO2014137797A3 (en) Stable glucokinase activator compositions
MY168438A (en) Handy calco-magnesian suspension
MX2010005714A (es) Compuestos de piridina.
MX2023006856A (es) Composiciones de polvo seco con estearato de magnesio.
TN2016000003A1 (en) New isoindoline or isoquinoline compounds, a process for their preparation and pharmaceutical compositions containing them
WO2012130820A3 (de) Isopentylester zur verwendung in kosmetischen, dermatologischen oder pharmazeutischen kompositionen
MX355885B (es) Composición farmacéutica de administración oral.
ES2530423A2 (es) Nuevas formas solidas de inhibidores de la fosfodiesterasa tipo 5
WO2015092810A3 (en) Amorphous form of idelalisib
IN2015DN00833A (OSRAM)
IN2014DN01619A (OSRAM)
HUE049298T2 (hu) Szitagliptin tartalmú stabil gyógyszerészeti készítmények azonnali hatóanyag leadású tabletta formájában
WO2014083580A3 (en) Pharmaceutical compositions of regadenoson
WO2016049185A3 (en) Synthetic rhinoceros horn analogues
PL3041364T3 (pl) Stosowanie środka przeciwzbrylającego dla poprawy twardości gumy do żucia zawierającej maltitol w postaci proszku
EA032913B1 (ru) Препараты производных пиримидиндиона